CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference

Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloSeq® portfolio of pre- and post-transplant solutions for human leukocyte antigen (HLA) typing, including QTYPE®, and post-transplant hematopoietic stem cell and organ transplant surveillance during poster presentations and the symposium taking place at this year’s EFI 2022 Conference.

The joint 2022 European Federation for Immunogenetics (EFI) and Histocompatibility Conference takes place from May 17 to May 20 in Amsterdam, the Netherlands.

"CareDx is a global leader in transplant, and Europe is our largest commercial presence outside the U.S. As such, we are proud to bring innovative, best-in-class solutions to researchers, laboratories, and clinicians in Europe with our AlloSeq franchise, including AlloSeq Tx17 and Tx9 for HLA typing, AlloSeq cfDNA for organ transplant monitoring, and AlloSeq HCT for hematopoietic stem cell monitoring research,” said Reg Seeto, CEO and President of CareDx. "There are few companies 100% dedicated to transplant, which is what makes CareDx’s mission and commitment so unique and important for transplant patients.”

CareDx will be on hand to showcase its leadership in serving European laboratories, researchers, and clinicians with its leading product portfolio of next-generation sequencing (NGS) based AlloSeq products, which serve pre- and post-transplantation. For pre-transplant, CareDx offers HLA typing solutions, QTYPE, AlloSeq Tx17, and newly introduced AlloSeq Tx9, covering 9 key HLA loci. For post-transplantation monitoring, CareDx offers AlloSeq HCT chimerism testing using NGS for research use only and AlloSeq cfDNA for labs to assess transplanted organ health. Additionally, CareDx provides pre-transplant HLA typing and post-transplant surveillance testing for customers wanting to use its service lab in Stockholm, Sweden, for clinical research.

"Together with CareDx, we are working on several projects for which we use the AlloSeq Tx17 kits for high-resolution HLA typing, as well as the AlloSeq cfDNA kits for detecting cell-free DNA,” said Sebastiaan Heidt, Associate Professor, Leiden University Medical Centre, and group leader and organizer of EFI 2022. "CareDx’s innovative assays allow us to answer research questions that were previously not possible to address.”

CareDx Symposium: "Advancing Patient Care: Pre- and Post-Transplant Solutions to Improve the Patient Journey,” will be held on Wednesday, May 18, 1-2pm CEST. For more detailed agendas, speakers, and to register please follow this link.

The following AlloSeq data will be presented:

About CareDx – The Transplant Company

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx’s AlloSeq® portfolio, including QTYPE®, and CareDx’s presentations at EFI 2022 Conference regarding the latest information on its AlloSeq portfolio of pre-and post-transplant solutions (the "Presentations”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of the AlloSeq portfolio, including QTYPE, or Presentations; risks that EFI 2022 Conference and the agendas of CareDx symposium fail to take place as planned; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by CareDx with the SEC on February 24, 2022, the quarterly report on Form 10-Q for the first quarter of 2022 ended on March 31, 2022 filed by CareDx with the SEC on May 5, 2022, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

CONTACTS:
CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com 

Investor Relations
Ian Cooney
(415) 722-4563
investor@CareDx.com